JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M602349200 on May 9, 2006

J. Biol. Chem., Vol. 281, Issue 27, 18307-18316, July 7, 2006
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Supplemental Data
Right arrow All Versions of this Article:
281/27/18307    most recent
M602349200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schindler, K.
Right arrow Articles by Winter, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schindler, K.
Right arrow Articles by Winter, E.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Phosphorylation of Ime2 Regulates Meiotic Progression in Saccharomyces cerevisiae*Formula

Karen Schindler and Edward Winter1

From the Department of Biochemistry and Molecular Biology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107

Received for publication, March 13, 2006 , and in revised form, May 5, 2006.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Ime2p is a meiosis-specific protein kinase in Saccharomyces cerevisiae that controls multiple steps in meiosis. Although Ime2p is functionally related to the Cdc28p cyclin-dependent kinase (CDK), no cyclin binding partners that regulate its activities have been identified. The sequence of the Ime2p catalytic domain is similar to CDKs and mitogen-activated protein kinases (MAPKs). Ime2p is activated by phosphorylation of its activation loop in a Cak1p-dependent fashion and is subsequently phosphorylated on multiple residues as cells progress through meiosis. In this study, we show that Ime2p purified from meiotic cells is phosphorylated on Thr242 and Tyr244 in its activation loop and on Ser520 and Ser625 in its C terminus. Ime2p autophosphorylates on threonine in its activation loop in vitro consistent with autophosphorylation of Thr242 playing a role in its activation. Moreover, autophosphorylation in cis is required for Ime2p to become hyperphosphorylated. Phosphorylation of the C-terminal serines is not essential to sporulation. However, Ime2p C-terminal phosphorylation site mutants genetically interact with components of the FEAR network that controls exit from meiosis I. These data suggest that Ime2p plays a role in controlling the exit from meiosis I and demonstrate that a phospho-modification pathway regulates Ime2p during the different phases of meiotic development.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Meiosis is the program by which diploid cells generate haploids. It shares several key processes with mitosis including DNA replication and chromosome segregation; however, its successful completion requires a series of processes unique to meiosis. These meiosis-specific processes include homolog pairing, synaptonemal-complex formation, genetic recombination, and a reductional division (MI). Subsequently, an equational (mitosis-like) division (MII) occurs without an intervening round of DNA replication. Completion of MII is linked to specialized differentiation programs that produce gametes capable of sexual fusion. Meiosis-specific processes are induced in part, through transcriptional programs that express meiotic genes as they are needed. These programs also express signaling molecules that are required to coordinate meiotic processes and superimpose meiotic regulation on the mitotic cell cycle machinery.

In Saccharomyces cerevisiae multiple meiotic processes are regulated by the Ime2p meiosis-specific protein kinase. Ime2p is functionally related to Cdc28p, the sole essential cyclin-dependent kinase (CDK)2 required for mitosis and meiosis. IME2 transcription begins shortly after meiotic induction and increases further around the time of the chromosomal divisions. This biphasic accumulation of IME2 mRNA first requires Ime1p, the transcription factor specific for the early class of meiosis-specific promoters (1). Its second phase of transcription requires Ndt80p, the transcription factor specific for middle sporulation gene promoters (2).

After induction, Ime2p first positively regulates early gene expression through Ime1p. During this time, Ime2p controls meiotic S phase by functionally replacing some, but not all, of the Cdc28p mitotic S-phase-promoting roles (35). For example, whereas Cdc28p is required to target the Sic1p CDK inhibitor for ubiquitin-mediated proteolysis in mitosis, Ime2p is required for this role in meiosis. During the early phase of sporulation, Ime2p also phosphorylates replication protein A (6). Ime2p subsequently promotes the meiotic divisions at least in part by positively regulating Ndt80p through direct phosphorylation (4, 7). In addition, genetic evidence suggests that Ime2p negatively regulates Sum1p, a repressor protein that functions in opposition to Ndt80p (8). Ime2p also plays a role in terminating early gene expression by promoting the destruction of Ime1p (9). Later in the program, Ime2p has been proposed to negatively regulate Cdh1p, a targeting subunit of the anaphase-promoting complex/cyclosome and may thus regulate chromosome segregation by modulating the activity of this ubiquitin ligase (10). A subset of Ime2p function may be carried out (albeit inefficiently) by Cdc28p in ime2 mutants (5).

These collective observations demonstrate that Ime2p regulates multiple meiotic processes. Although Ime2p is functionally related to Cdc28p, no cyclin binding partners have been identified that regulate its activity, and relatively little is known about how its multiple functions in meiosis are controlled. Ime2p is degraded shortly after MII is completed (4). Ubiquitin-mediated destruction of Ime2p occurs in a Grr1p-dependent manner when glucose, which inhibits meiosis, is added to sporulating cells (11). In addition, it has been proposed that glucose can inhibit the Ime2p activity through the Gpa2p heterotrimeric GTP-binding protein (12).

In previous studies it was shown that Ime2p is phosphorylated early in sporulation and hyperphosphorylated during middle sporulation (4, 13). Ime2p contains a TXY motif in its activation loop that is similar to the activation loops found in mitogen-activated protein kinases (MAPKs). Mutations of either the Thr or Tyr lead to a decrease in Ime2p activity suggesting that these might be sites of activating phosphorylation (13). Interestingly, phosphorylation and activation of Ime2p requires Cak1p, which also activates Cdc28p by phosphorylation of its activation loop. Aspects of this mechanism for activating Ime2p may be evolutionarily conserved in higher eukaryotes since ICK, a mammalian protein kinase with sequence similarity to Ime2p, can be directly phosphorylated by yeast Cak1p (14). Full modification of Ime2p is dependent on its own catalytic activity and Ime2p autophosphorylates in vitro (13).

Cdc28p activity is controlled by multiple mechanisms including phosphorylation and the binding of activators and inhibitors. During vegetative growth, Cdc28p activity is down-regulated to allow cells to exit from the mitotic division (15). There are two pathways that work in conjunction to control exit from mitosis: the cdc fourteen early anaphase release (FEAR) and the mitotic exit network (MEN) (15, 16). These pathways negatively regulate Cdc28p by controlling release of the Cdc14p dual-specificity phosphatase from the nucleolus. Cdc28p must be active for execution of both meiotic divisions but it must also be down-regulated between meiosis I (MI) and meiosis II (MII) (4, 17). Data from several groups indicate that FEAR, and not MEN, is central to regulating the exit from MI (1820). Cells harboring mutations in the FEAR network (SLK19, SPO12, and CDC14) are defective in downregulating Cdc28p and disassembling the MI spindle. These cells complete a mixed MI/MII division on the persistent MI spindle and generate dyad rather than tetrad spores. Because cells lacking IME2 block early in the program more is known about its earlier roles than its later roles and it is unclear whether it participates in FEAR network regulation. Ime2p appears to be required for meiotic M phase; however, it is unclear how its activity is controlled during the meiotic divisions.

Here, we used mass spectrometry of Ime2p purified from meiotic cells and phosphopeptide mapping of in vitro autophosphorylation reactions to identify phosphoacceptor sites in Ime2p and address their significance in Ime2p regulation. We demonstrate that Thr242 and Tyr244 are phosphorylated in a Cak1p-dependent manner consistent with our previous genetic studies (13). Furthermore, we found that Ime2p autophosphorylates its activation loop. In addition, we found that the C-terminal regulatory domain of Ime2p is phosphorylated on Ser520 and Ser625 during a time in which cells are completing the meiotic divisions. Mutants lacking these phosphorylation sites show an increase in dyad formation and genetically interact with mutants in the FEAR network. These data provide insight into the mechanism of Ime2p activation and its regulation by phosphorylation during sporulation.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Strain and Plasmid Construction—The yeast strains and plasmids used in this study are described in Tables 1 and 2, respectively. All strains except for those harboring the galactose-inducible IME2 plasmids are in the SK1 genetic background. The IME2 mutant alleles were generated by site-directed mutagenesis (QuikChange, Stratagene) of pAM4, pMRC5, and pCM1. The Ser246 codon was mutated from TCC to GCC. Codons Ser520 and Ser625 were changed to alanines by mutating TCA to GCC. These alleles were integrated in the chromosome by transforming the ime2::URA3 strain KBY443 (a gift from Kirsten Benjamin) with SacII/SmaI-digested pAM4-derived DNA and with SacII/KpnI-digested pCM1-derived DNA followed by selection of FOA-resistant colonies. Plasmid pCM1 was generated by subcloning a SpeI/KpnI fragment from pAM4 into pRS316 cut with SpeI and KpnI and pMRC5 was generated by subcloning a SalI/NotI fragment from pMR1 into pRS316 cut with SalI and NotI (13).


View this table:
[in this window]
[in a new window]
 
TABLE 1
Yeast strains used in this study

 


View this table:
[in this window]
[in a new window]
 
TABLE 2
Plasmids used in this study

 
Media and Growth Conditions—Vegetative growth was maintained in YEPD (1% yeast extract, 2% peptone, 2% glucose), S.D. (0.67% yeast nitrogen base without amino acids, 2% glucose, plus nutrients essential for auxotrophic strains) or YEPA (1% yeast extract, 2% peptone, 2% potassium acetate). For synchronous sporulation, cells were grown in YEPA to an A600 of 0.3–0.5. Prior to sporulation, cells were harvested, washed in SM (2% potassium acetate plus 10 µg of adenine, 5 µg of histidine, 30 µg of leucine, 7.5 µg of lysine, 10 µg of tryptophan, and 5 µg of uracil per ml) and resuspended in SM at 2 OD/ml.

DNA Staining and Analysis—To monitor the meiotic divisions, 1 OD of cells was taken at various times, fixed in 90% EtOH, and stained with 1 µg/ml of 4',6-diamidino-2-phenylindole (DAPI). The completion of MI and MII were scored by counting the proportion of cells containing two DAPI-staining bodies and more than two DAPI-staining bodies observed by fluorescence microscopy. One hundred cells in 3–7 independent isolates per mutant were analyzed.

Protein Isolation and Analysis—Whole cell lysates were prepared as described previously (13). Samples were loaded on 7.5% polyacrylamide gels, run at 12 mV, transferred to Immobilon-P (Millipore), and blocked overnight at 4 °C in phosphate-buffered saline, 0.1% Tween-20 plus I-Block (Tropix). Antibody staining was performed for 1 h at room temperature with a polyclonal antibody against Ime2p (1:10,000) (21). After washing, the membrane was incubated for 30 min at room temperature with a secondary anti-rabbit antibody (Promega, 1:7,500). The Myc epitope on Ime2p was detected with a 9E10 monoclonal antibody (Santa Cruz Biotechnology; 1:1,000) and the HA epitope was detected with a HA.11 monoclonal antibody (Babco; 1:5,000) and a secondary anti-mouse (Promega; 1:5,000). The secondary antibodies were conjugated to alkaline phosphatase and were detected by chemiluminescence (CDP-Star, Tropix).

Kinase Assays—Ime2p-myc kinase assays were conducted as described previously (13). Briefly, 20 ODs of sporulating cells were harvested and frozen in liquid nitrogen at 2-h post-induction. Next, the cells were lysed by 3 cycles of 1-min bursts of bead beating followed by 2 min on ice (500 µl of 0.5 µm glass beads, Sigma) in 500 µl of lysis buffer (50 mM HEPES, pH 7.4, 75 mM KCl, 1 mM EGTA, 1 mM MgCl2, 0.1% Nonidet P-40, 50 mM NaF, 50 mM beta-glycerolphosphate, 1 mM Na3VO4, 1mM phenylmethylsulfonyl fluoride, 8.8 µg/ml aprotinin, 4 mg/ml antipain, 0.1 µg/ml pefabloc SC, 2 µg/ml pepstatin A, 1 µg/ml chymostatin, 1 mM benzamidine, and 2 µg/ml leupeptin). Protein from clarified supernatants were used for immunoprecipitation of Ime2p-myc with 20 µl of 1:1 slurry of protein A-agarose beads (Roche Applied Science) and 60 µl of anti-Myc antibody (A-14, Santa Cruz Biotechnology; 200 µg/ml) or anti-HA antibody (Y-11, Santa Cruz Biotechnology; 200 µg/ml) by gentle mixing at 4 °C for 8–24 h. Immunoprecipitates were collected and washed three times in lysis buffer and once in kinase buffer (20 mM HEPES, pH 7.4, 100 mM KCl, 10 mM MgCl2). The immunoprecipitates were stored in a 1:1 mixture of kinase buffer and 100% glycerol at –20 °C until processing. Desired amounts of sample were removed from the stock, washed in kinase buffer, and resuspended in 25 µl of kinase buffer containing 5 µCi of [{gamma}-32P]ATP (PerkinElmer Life Sciences) and 1 µM cold ATP. The reactions were terminated after a 30-min incubation at 30 °C with the addition of SDS gel loading buffer followed by boiling. Samples were resolved on 7.5% polyacrylamide gels, dried, and processed by autoradiography or phosphorimaging (Molecular Dynamics).

Phosphoamino Acid Analysis—Ime2p-myc was isolated from sporulating cells by immunoprecipitation and autophosphorylated as described above. Protein isolation and hydrolysis was conducted as described by Boyle et al. (22). The autophosphorylated material was eluted from a dried 7.5% acrylamide gel by shaking overnight at 37 °C in 50 mM NH4HCO3, 0.1% SDS, and 0.5% 2-mercaptoethanol. The eluted protein was concentrated by precipitation with 20% trichloroacetic acid and washed in cold acetone prior to hydrolysis in 6 N HCl at 110 °C for 1 h. The hydrolyzed material was lyophilized and resuspended in 5 mM Tris-Cl, pH 8 containing 60 µg/ml of cold phosphoamino acid standards (Sigma). 5–8 µls of each sample were spotted onto plastic-backed, cellulose TLC plates (Kodak). Ascending chromatography was performed in a brick TLC tank pre-equilibrated with isobutyric acid-0.5 M NH4OH (5:3, v/v). After drying, the cold standards were visualized with ninhydrin (0.25% in acetone; Sigma), baked at 65 °C for 15 min, and developed by either autoradiography or phosphorimaging.

Phosphopeptide Mapping—Autophosphorylated Ime2p was isolated and concentrated as described above. After washing, the protein was oxidized in ice-cold performic acid at 0 °C for 1 h and lyophilized. Next, the protein was digested overnight at 37 °C in 50 mM NH4HCO3 containing either 10 µg of TPCK-trypsin or chymotrypsin (Worthington). Finally, the sample was lyophilized and washed several times in pH 1.9 buffer (formic acid (88%), glacial acetic acid, and deionized water (25: 78:897, v/v/v)) before resuspension in 5 µl of pH 1.9 buffer. The sample was spotted onto glass-backed 100 µm 20 x 20 cm microcrystalline cellulose TLC plates (EM Scientific) along with 5 µl of 5 mg/ml {epsilon}-dinitrophenyl-lysine and 1 mg/ml xylene cyanol FF as a standard. First, the plate was subjected to electrophoresis in pH 1.9 buffer using a Hunter thin-layer electrophoresis unit 7000 (HTLE, CBS Scientific, Inc) for 45 min at 1.0 kV (10–15 mA). After drying, ascending chromatography was conducted in a glass-brick TLC tank pre-equilibrated with isobutyric acid, n-butyl alcohol, pyridine, acetic acid, and water (65:2:5:3:29). Phosphopeptides were detected by phosphorimaging, and exposure times were adjusted so that the spots were of equal intensities to compare wild-type and catalytically weakened Ime2p reactions.

Protein Purification and Mass Spectrometry—Three liters of wild-type and cak1-{Delta} cells harboring a chromosomally-integrated allele of IME2-myc were grown overnight at 30 °C in YEPA to an OD of 0.5 prior to sporulation at 2 OD/ml in SM. After 7.5 h cells were harvested, washed, and concentrated in a small volume of ice-cold water plus 25 mM beta-glycerolphosphate, 1 mM Na3VO4, 100 µg/ml phenylmethylsulfonyl fluoride, and a mixture of protease inhibitors (8.8 µg/ml aprotinin, 4 mg/ml antipain, 0.1 µg/ml pefabloc SC, 2 µg/ml pepstatin A, 1 µg/ml chymostatin, 1 mM benzamidine, and 2 µg/ml leupeptin). The concentrated cells were frozen dropwise in liquid nitrogen prior to grinding into a fine powder with a mortar and pestle in liquid nitrogen and transferring into a 250-ml centrifuge tube (Corning 430776). The cells were lysed in the centrifuge tube in 50 ml of lysis buffer (50 mM Tris-Cl, pH 7.4, 75 mM KCl, 1 mM EGTA, 1 mM MgCl2, 0.1% Nonidet P-40, 50 mM NaF, 50 mM beta-glycerolphosphate, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl fluoride, and the protease inhibitor mixture described above) using a prechilled Polytron homogenizer. Next, the lysate was clarified by centrifugation at 31,000 rpm (110,000 x g) in a Beckman Ultracentrifuge Ti 55.2 for 1.5 h at 4 °C. The clarified lysate was pumped at 1 ml/min over a pre-equlibrated HiTrapp Q FF ion exchange column from Amersham Biosciences. After washing with lysis buffer containing 0.2 M KCl, Ime2p-myc was eluted in 15 ml of lysis buffer containing 0.4 m KCl. To further purify Ime2p-myc, the eluate was immunoprecipitated overnight at 4 °C with 120 µl of a 1:1 slurry of protein A-agarose beads and 250 µl of anti-Myc antibody (A-14, Santa Cruz Biotechnology, 200 µg/ml). The immunoprecipitated proteins were reduced with 10 mM dithiothreitol in 0.1 M NH4HCO3 and alkylated with 0.5 M iodoacetamide in 0.1 M NH4HCO3 prior to elution from the beads by boiling in a SDS-containing loading buffer and resolving on a 7.5% polyacrylamide gel.

Coomassie-stained Ime2p-myc bands were excised from the gel, washed, and destained in 50% methanol overnight, dehydrated in acetonitrile, and rehydrated in the reducing and alkylating agents described above. MS analysis was performed at the W. M. Keck Biomedical Mass Spectometry Laboratory at the University of Virginia. Gel slices were dehydrated a second time, dried by vacuum centrifugation, rehydrated, and digested overnight at 37 °C in 20 mg/ml trypsin in 50 mM NH4HCO3. Peptides were extracted twice using 50% acetonitrile and 5% formic acid, pooled and injected into a Finnigan LCQ DecaXP ion trap mass spectrometer system with a Protana nanospray ion source (operated at 2.8 kV) interfaced to a Phenomenex Jupiter 10-µm C18 reversed-phase capillary column. Peptides were eluted from the column by an acetonitrile/0.1 M acetic acid gradient at a flow rate of 0.25 µl/min. The digest was analyzed using acquired full mass spectra to determine the molecular weights of the peptides followed by 4 product ion spectra to determine amino acid sequence. The data were analyzed by Sequest search algorithm for matching peptides.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
The Ime2p Activation Loop and C-terminal Regulatory Domain Are Phosphorylated in Vivo—To gain insight into how phosphorylation regulates Ime2p, we developed a method to purify phosphorylated Ime2p from sporulating cells suitable for phosphosite identification using mass spectral (MS) analysis. Overexpression of IME2 is lethal to mitotically growing cells and may have negative effects on sporulation (10, 21).3 Furthermore, we wanted to identify phosphorylation sites that are modified during wild-type sporulation conditions. We therefore chose to purify Ime2p using a strain in which Myc epitope coding information had been integrated at the chromosomal IME2 locus.

Cells of the rapidly sporulating SK1 genetic background were collected at 7.5-h post-induction, when the meiotic divisions are occurring and Ime2p is most abundant and hyperphosphorylated (Refs. 4 and 13 and Fig. 1). Extracts were prepared by mechanical disruption, clarified by ultracentrifugation, and passed over a S-Sepharose anion-exchange resin (see "Experimental Procedures"). Ime2p-myc was subsequently collected by a stepwise 0.2–0.4 M KCl elution and further purified by Myc immunoprecipitation followed by polyacrylamide gel electrophoresis. Coomassie-stainable amounts of Ime2p-myc obtained from wild-type and cak1-{Delta} cells (non-phosphorylated control) were analyzed by LC/MS. This analysis was conducted twice using three different proteases to maximize sequence coverage. 67% of Ime2p sequence purified from wild-type cells and 68% of Ime2p sequence purified from cak1-{Delta} cells were analyzed between the three protease-treated samples.

Both Thr242 and Tyr244 were identified as phosphorylated residues in wild-type cells and not in cak1-{Delta} cells (Table 3 and supplementary Fig. S1). In the tryptic peptide analysis the activation loop was identified as a mixture of two phosphoforms: phosphorylated on Tyr244 alone and doubly phosphorylated on Thr242 and Tyr244. These data are consistent with the Tyr244 being phosphorylated prior to Thr242 phosphorylation (see "Discussion"). Furthermore, Tyr244 was also identified as phosphorylated in the chymotryptic analysis. These phosphorylated peptides were identified in two independent experiments and directly confirm our previous suggestion that these residues are phosphorylated in a Cak1p-dependent manner during sporulation (13).


View this table:
[in this window]
[in a new window]
 
TABLE 3
Ime2p-myc peptides modified with phosphate in WT (KSY187) cells, not in the cak1-{Delta} control (KSY138)

Ionization spectra can be found in Fig. S1.

 
Two serine residues located in the C terminus of Ime2p were also identified as phosphorylated in wild-type cells and not in the cak1-{Delta} control (Table 3 and supplementary Fig. S1). Phosphorylated Ser520 was identified in both the trypsin and AspN protease digestions. Both digests contained a mixture of phosphorylated and non-phosphorylated Ser520-containing peptides (Table 3 and data not shown). Ser625 was identified as being in an exclusively phosphorylated form in the tryptic digest. Both the Ser520- and Ser625-phosphorylated peptides were identified in two independent experiments.


Figure 1
View larger version (44K):
[in this window]
[in a new window]
 
FIGURE 1.
The electrophoretic mobility of Ime2p-S520A/S625A is different from wild type. Protein was isolated from whole cell lysates of sporulating cells at the indicated times from ime2-{Delta} diploid cells (KSY233) containing plasmids encoding wild-type or S520A/S625A IME2 alleles and probed with a polyclonal antibody against Ime2p. The asterisk indicates a cross-reacting species used as a loading control.

 
To confirm that Ser520 and Ser625 are sites of phosphorylation we generated single S520A and S625A and double S520A/S625A IME2 mutants and analyzed the electrophoretic migration of the encoded proteins by Western immunoblotting. For these studies we used IME2-containing plasmids that lack the Myc epitope because phosphoforms of untagged Ime2p are more readily resolved from one another than tagged Ime2p (data not shown). As previously reported, when Ime2p is induced in meiotic cells, it is rapidly phosphorylated in a CAK1-dependent fashion. Ime2p therefore migrates slightly slower than unphosphorylated Ime2p when cells are in meiotic S phase and prophase (2–5 h post-induction) (38). Hyperphosphorylated forms of Ime2p begin to accumulate around 5–6 h (Fig. 1 and Ref. 13). At this time, the overall level of Ime2p increases as active Ndt80p accumulates, and cells enter MI. Ime2p levels begin to decline (at ~10 h) as cells complete MII and initiate spore formation. Mutation of Ser520 and Ser625 to alanines, both singly and in combination, did not reproducibly affect the timing of Ime2p production, its electrophoretic mobility at early (2–5 h) time points (Fig. 1), or its disappearance after MII has been completed (data not shown). However, the electrophoretic mobilities of these mutant proteins were different than the wild type at the 6–10 h time points, with relative amounts of the slowest migrating forms of Ime2 being reduced in abundance (Fig. 1 and data not shown). More modest electrophoretic migration differences were seen in the single mutant samples; however, the electrophoretic mobility of the double S -> A mutant is most similar to the S520A single mutant (data not shown). The mobilities of the mutant Ime2p proteins were indistinguishable from wild type when expressed in cak1-{Delta} cells, where Ime2p is not phosphorylated (data not shown, Ref. 13) demonstrating that these mutations do not simply change the electrophoretic migration of Ime2p. The Ime2p mobility differences we observed are consistent with the MS data and confirm that Ser520 and Ser625 are phosphorylated during sporulation. The time when the mobility differences are observed corresponds to the interval when the meiotic divisions occur in this strain background (see Fig. 5). Because the doubly mutant protein is still partially modified during middle sporulation, other phosphorylation sites that have not been identified likely exist. We note that our MS analysis covered 2/3 of Ime2p and suggest that 1 or more sites of phosphorylation exist in the remaining uncovered region.


Figure 2
View larger version (86K):
[in this window]
[in a new window]
 
FIGURE 2.
Ime2p autophosphorylates its activation loop. Two-dimensional phosphopeptide maps were generated from in vitro autophosphorylated Ime2p. Tryptic (A) and chymotryptic (C) phosphopeptide maps of Ime2p-myc (KSY187). Tryptic (B) and chymotryptic (D) phosphopeptide maps of Ime2p-Y244F-myc (KSY216). The origins are marked with a circle, and the major spot is marked with an arrow.

 
Ime2p Autophosphorylates Its Activation Loop but Not the C-terminal Serines—We and others (4, 7, 13), have previously shown that Ime2p phosphorylates itself in vitro. Moreover, a catalytically inactive form of Ime2p is not hyperphosphorylated during sporulation (Ref. 13 and see below). These observations suggest that the sites of Ime2p autophosphorylation are relevant to understanding the Ime2p phosphomodification pathway. We used thin-layer electrophoresis followed by chromatography to generate two-dimensional tryptic and chymotryptic phosphopeptide maps of Ime2p autophosphorylation reactions (see "Experimental Procedures"). The tryptic phosphopeptide map of the wild-type autophosphorylated protein showed that Ime2p autophosphorylates primarily on one peptide and several minor peptide species (Fig. 2A). The electrophoretic migration of the major peptide is consistent with the predicted migration of the doubly phosphorylated activation loop peptide (residues 239NPYTAYVSTR248). To test whether the major autophosphorylated peptide corresponds to the Ime2p activation loop, we analyzed Ime2p-Y244F autophosphorylation reactions (Fig. 2, B and D). This mutant protein autophosphorylates to a decreased level (~20% of wild-type) and a homozygous ime2-Y244F strain shows a decreased ability to promote sporulation consistent with Tyr244 being a site of activating phosphorylation (13). Because the Y224F mutant autophosphorylates with a reduced efficiency, we extended the exposure times of these TLC plates to compare the peptide positions with the positions on the wild-type plates. The mutant Y244F activation loop protein also autophosphorylated on one major tryptic peptide; however, the mutant peptide migrated further than the wild-type peptide in the chromatographic dimension (compare Fig. 2, A to B). The chromatographic mobilities of the major autophosphorylated Y244F mutant and wild-type peptides were also different in the chymotryptic analysis (compare Fig. 2, C to D). These changes in chromatographic migration are consistent with the difference in hydrophobicities between phosphotyrosine and phenylalanine, suggesting that Ime2p autophosphorylates its own activation loop in vitro. These data are also consistent with the MS data demonstrating that Tyr244 is phosphorylated (Table 3). We note that the interpretation of the chymotryptic map in Fig. 2C is most likely complicated by chymotrypsin-inefficient cleavage after phosphotyrosine. Changing Tyr244 to a Phe alleviates this complication making the interpretation of Fig. 2D more straightforward.


Figure 3
View larger version (55K):
[in this window]
[in a new window]
 
FIGURE 3.
Ime2p autophosphorylates on threonine and serine. Phosphoamino acid analyses of autophosphorylated Ime2p-myc (KSY187), Ime2p-S246A-myc (AMY25), and Ime2p-S5250A/S625A-myc (KSY348). Hydrolysates were spotted on a TLC plate with phosphoamino acid standards. Phosphoamino acid content was analyzed using ascending TLC. Positions of the ninhydrin-stained phosphoamino acid standards are indicated with arrows. The phosphoamino acid content was detected by autoradiography and alignment of the ninhydrin-stained plate with the film.

 
The activation loop peptide contains 2 threonines (Thr242 and Thr247), 2 tyrosines (Tyr241 and Tyr244), and a single serine (Ser246). Phosphoamino acid analyses demonstrate that only threonine and serine, in a roughly 2:1 ratio, are autophosphorylated (Fig. 3). Thus, the tyrosines are not sites of autophosphorylation. Furthermore, the activation loop serine is not a site of autophosphorylation because both the phosphothreonine:phosphoserine ratio and the total efficiency of autophosphorylation was indistinguishable between the wild type and S246A mutant (Fig. 3 and data not shown). The electrophoretic migration of the major autophosphorylated tryptic peptide in the wild-type Ime2p reaction is inconsistent with it containing more than 2 phosphates. Mutation of Tyr244 to a Phe introduces a chymotrypsin recognition site between Thr242 and Thr247. Importantly, the chymotryptic phosphopeptide map of this mutant contains only a single major autophosphorylated peptide (Fig. 2D). Therefore, these data demonstrate that either Thr242 or Thr247 is the major autophosphorylation site. We were not able to unambiguously distinguish the chymotryptic Tp-AF-(242–244) peptide versus a VS-Tp-RW-(245–249) peptide based solely on their predicted mobilities. Both the T242A and T247A mutations almost completely abolish Ime2p autocatalysis in vitro, and therefore we are unable to generate phosphopeptide maps for these mutant alleles (Ref. 13 and data not shown). We have previously demonstrated that premeiotic S and M phases are delayed by ~3 h in a homozygous ime2-T242A mutant (13). Importantly, our MS data identified Thr242 and not Thr247 as being a site of phosphorylation in vivo (Table 3). Taken as a whole, the data indicate that Thr242 is the major site of Ime2p autophosphorylation and that this reaction positively regulates Ime2p. Interestingly, this residue aligns with the residue in Cdc28p that is directly phosphorylated by Cak1p (Thr169) (Refs. 23 and 24; see "Discussion"; Table 3). The minor species in the phosphopeptide maps represent 1 or more peptides that are autophosphorylated on serine and may also represent improperly cut activation loop peptides or activation loop peptides containing various amounts of incorporated phosphate (Fig. 2). The positions of some of the minor species are different in the wild type and Y244F mutant samples, suggesting that these are autophosphorylated activation loop peptide products. The incorporation of radioactivity in these species was close to background levels; therefore we did not further investigate their identity.


Figure 4
View larger version (29K):
[in this window]
[in a new window]
 
FIGURE 4.
Ime2p autophosphorylation in cis is required for accumulation of hyperphosphorylated Ime2p. Whole cell lysates were prepared from sporulating cells of the indicated genotype at 4-h post-induction. Ime2p-myc protein was analyzed by immunoblot analysis with an antibody against the Myc epitope.

 
Because the autophosphorylated serine in Ime2p is located outside of the activation loop, we asked whether Ime2p autophosphorylates Ser520 or Ser625, which were identified in the MS experiments. We found that a double mutant Ime2p-S520A/S625A protein still contained the same 2:1 ratio of phosphothreonine:phosphoserine seen in wild-type Ime2p autophosphorylation reactions (Fig. 3). Furthermore, the tryptic phosphopeptide maps of the single and double serine mutants were indistinguishable from wild type (data not shown). These data suggest that Ime2p does not autophosphorylate Ser520 or Ser625 in vitro, consistent with another kinase phosphorylating these residues.

Ime2p Autophosphorylation Controls Ime2p in Vivo and May Occur via an Intramolecular Mechanism—We previously demonstrated that Ime2p is activated by phosphorylation in a Cak1p-dependent fashion (13). Following activation, Ime2p is sequentially phosphorylated on multiple residues and accumulates in a hyperphosphorylated state around the time when the meiotic divisions are occurring. In this same study we showed that a catalytically inactive form of Ime2p fails to become hyperphosphorylated. However, because active Ime2p is required for meiotic S phase (a process that occurs prior to its hyperphosphorylation), these studies did not establish whether the failure of inactive Ime2p to become hyperphosphorylated reflects a direct requirement of Ime2p catalytic activity or a consequence of the ime2 mutant blocking early in the program. To gain further insight into the role of Ime2p autophosphorylation in vivo, we compared the phosphorylation of Myc-tagged wild type and catalytically inactive (K97R) Ime2p expressed alone, or in combination with wild-type Ime2p that lacked the Myc epitope. As previously reported, Ime2p-myc from a IME2-myc/IME2-myc homozygous diploid strain migrated more slowly than Ime2p-myc from cells lacking CAK1 (Fig. 4; compare lanes 1–5). Ime2p-myc from the homozygous control strain migrated slower than Ime2p-K97R-myc (Fig. 4; compare lanes 1, 4, and 6). Importantly, when Ime2p-K97R-myc was made from a heterozygous ime2-K97R-myc/IME2 strain it was never modified like wild type, despite the fact that these cells completed sporulation (Fig. 4; compare lane 1 to lane 2). Even when wild-type IME2 was produced from a multicopy plasmid, Ime2pK97R-myc was not hyperphosphorylated (Fig. 4; lane 3). These results suggest that the autophosphorylation of Ime2p plays an essential role in the Ime2p phosphomodification pathway in vivo. These data further suggest that Ime2p may be autophosphorylated by an intramolecular mechanism.

Phosphorylation of Ser520 and Ser625 Regulate Ime2p—To study the regulatory role that phosphorylation of Ser520 and Ser625 has on Ime2p and sporulation we generated strains containing chromosomally integrated serine-to-alanine substitutions at these positions, both singly and in combination. The single and double mutants completed meiosis, formed viable spores, and performed wild-type levels of genetic recombination at the HIS4 recombination hot spot (data not shown). Interestingly, we found a 3-fold increase in the frequency of dyads formed by the single and double mutant cells compared with wild type (Fig. 6A). In addition, we found that 9% ± 3% of the mutants cells formed asci with greater than four spores whereas <0.1% of wild-type cells formed asci with more than four spores. This supernumerary spore phenotype can occur after extra rounds of premeiotic DNA synthesis and was initially reported in genetic backgrounds where Cdc28p activity was deregulated (25, 26). Because Ime2p controls Cdc28p activity to stimulate meiotic S phase, it is possible that Cdc28p/Clb5p and Clb6p activity is elevated in the ime2-S520A/S625A mutant. Using the approach described by Strich et al. (43) we attempted to further up-regulate Cdc28p by overexpressing CLB1 using the strong ENO1 promoter in our IME2 mutant background but found no further increase in the frequency of asci with more than four spores (data not shown). These results indicate that phosphorylation of Ser520 and Ser625 is not essential for sporulation but may play a role in controlling interactions between Ime2p and Cdc28p.

We also monitored the time at which single and doubly mutant cells completed MI and MII by counting cells stained with DAPI (Fig. 5). Wild-type cells initiated MI between 5 and 6 h post-induction. As the percentage of cells that have completed MI peaks, cells that have completed MII begin to accumulate. In contrast to wild-type cells, both single and double ime2 mutants show an increased accumulation of cells in MI. The accumulation of MI cells was more severe in the S520A mutant than in the S625A-containing cells (compare Fig. 5, A to B). Notably, the interval separating MI and MII was increased in the phosphorylation site mutants. The increase in the MI peak and delay in MII suggest there may be a defect in regulating exit from MI. This phenotype is characteristic of mutants in the meiotic FEAR network that regulates Cdc28p activity (Refs. 17, 19, and 20 and see below). In addition, we note that the ime2-S520A/S625A mutant show a modest but reproducible advancement in the timing of MI (Fig. 5C).

The Ime2p C-terminal Phosphorylation Mutants Genetically Interact with Mutants in the FEAR Network—The IME2 C-terminal phosphorylation site mutant alleles were introduced into three FEAR-network mutants, and the percentage of cells completing one or two meiotic divisions was analyzed. Consistent with previously published data, slk19-{Delta} sporulation cultures contained a mixed population of cells completing one and two divisions (Fig. 6B and Refs. 17 and 20). The ime2-S520A/S625A allele substantially increased the frequency of cells completing a single division in the slk19 genetic background (from 26–69%). The temperature-sensitive cdc14-1 mutant sporulated at the semi-permissive temperature of 30 °C, also contained a mixed population of cells completing 1 and 2 divisions. The ime2-S520A/S625A allele further increased the frequency of single division cells (from 48–72%), similar to results with the slk19 mutant. Deletion of SPO12 caused the tightest FEAR phenotype with almost all cells completing a single division. The double ime2-S520/S625A spo12-{Delta} mutant had the same percentage of cells that completed a single division as the spo12-{Delta} single mutant. It is likely that the severe MI-exit defect of the spo12 mutant makes it difficult to observe any further difference when IME2 is mutated in this genetic background. Interestingly, both of the single IME2 serine mutant alleles in the slk19-{Delta} and cdc14-1 genetic backgrounds also increased the frequency of cells only able to complete 1 division. This data suggests that phosphorylation at both Ser520 and Ser625 function to regulate Ime2p during meiotic M phase and is consistent with the time at which we purified Ime2p for MS analysis. Taken together, these results suggest that Ime2p may function to regulate exit from MI. Because MI exit is, in part, controlled by down-regulating Cdc28p activity, these data also imply that Ime2p modulates Cdc28p activity during meiotic M phase.


Figure 5
View larger version (21K):
[in this window]
[in a new window]
 
FIGURE 5.
ime2-S520A and S625A mutants show defects in meiotic progression. Completion of meiosis I (MI) and meiosis II (MII) were monitored by fixing and DAPI staining cells at the indicted times during sporulation in IME2 (KSY187) (A–C), ime2-S520A (KSY318) (A), ime2-S625A (KSY319) (B), and ime2-S520A/S625A (KSY348) (C). Completion of MI (2 DAPI-staining bodies) and MII (more than 2 DAPI-staining bodies) was scored by fluorescence microscopy (n = 7).

 
A recent report from Kamieniecki et al. (19) suggested that the Cdc14p phosphatase controls Cdc28p activity between MI and MII through stabilizing the CDK inhibitor, Sic1p. This group found that expression of SIC1 driven by the sporulation-specific IME2 promoter suppressed the "FEAR phenotype" of the slk19-{Delta} mutant. This mutant expressing SIC1 contained fewer cells that blocked after a single division than slk19-{Delta} strains without the Sic1p plasmid. Ime2p regulates the destruction of Sic1p during meiotic S phase; however, it is unknown if it continues to regulate Sic1p later in the program (4, 27). We asked whether a multicopy plasmid expressing SIC1 from the IME2 promoter could suppress the dyad phenotype observed in the ime2 phosphorylation site mutant but found no difference in the frequency of cells that formed dyads (data not shown). This result suggests that Ime2p may be regulating meiotic M phase and Cdc28p in a Sic1p-independent mechanism or through multiple substrates.


Figure 6
View larger version (29K):
[in this window]
[in a new window]
 
FIGURE 6.
IME2 phosphorylation site mutants genetically interact with mutants in the FEAR network. A, percentage of dyads formed by wild-type (WT), and single and double mutant ime2 cells as indicated. B, percentage of dyads formed by ime2 phosphosite mutants in the slk19-{Delta}, cdc14-1, and spo12-{Delta} backgrounds as indicated. Cells of the indicated genotypes were sporulated for 24 h prior to fixation and DAPI staining (A: n = 7; B: n = 3).

 

    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Ime2p is a key meiosis-specific protein kinase that controls multiple steps in meiotic development. It is produced early in meiosis and is subsequently activated by phosphorylation in a Cak1p-dependent fashion (13). Later, it is phosphorylated on multiple residues as cells progress through the program. Ime2p accumulates in a hyperphosphorylated state during meiotic M phase and is subsequently degraded. It is likely that the phosphorylation of Ime2p not only activates its enzymatic activity, but also regulates multiple meiotic functions of the activated kinase. In this study we analyzed autophosphorylation reactions and used mass spectrometry of Ime2p purified from meiotic cells to identify residues in Ime2p that are phosphorylated. The data show that the activation loop of Ime2p is phosphorylated at Thr242 and Tyr244 in a Cak1p-dependent manner, consistent with our previously published genetic findings (Ref. 13 and Table 3). In addition, we show that Ime2p autophosphorylates its activation loop (Fig. 2). Finally, we found that Ser520 and Ser625 located in the C-terminal regulatory domain of Ime2p are phosphorylated when cells are undergoing the meiotic divisions and that mutants lacking phosphorylatable residues at these positions display modest defects in the timing of the meiotic divisions and genetically interact with FEAR network mutants (Fig. 5). These results are relevant to understanding how phosphorylation controls Ime2p during meiosis and demonstrate a previously unrecognized role for Ime2p in regulating the transition between MI and MII.

Ime2p Activation—Many protein kinases are activated by phosphorylation of activation loop residues that cause local and global structural changes that promote catalytic activity and substrate interactions (28). Thr242 and Tyr244 in Ime2p align with the sites of activating phosphorylation (TXY motifs) in MAPKs. Furthermore, Ime2p and MAPKs share similar catalytic cores (5 of the 10 most similar yeast proteins identified by BLAST comparisons are MAPKs). Structural studies have demonstrated that phosphorylation of the TXY motif in the mammalian ERK2 MAPK changes the conformation of the activation loop and activates the enzyme by causing changes to the active site and substrate specificity pocket (29). The sequence similarity between Ime2p and MAPKs and the demonstration that the TXY motif in Ime2p is phosphorylated suggest that Ime2p is activated by structural changes that are comparable to the changes seen in ERK2. Despite these similarities, the pathway that activates Ime2p does not appear to require a dual specificity MAPKK-like enzyme (see below).

Although phosphorylation by upstream kinases is generally thought to activate many kinases, several recent reports demonstrate that autophosphorylation plays an important role in activation among a diverse group of kinases (3033). This study indicates that Ime2p autophosphorylates its activation loop at Thr242. In a previous study, we demonstrated that Ime2p-T242A purified from meiotic cells showed dramatically reduced autophosphorylation in vitro (less than 5% of the level seen in the wild-type enzyme) (13). The ability of the Ime2p-Y244F protein to autophosphorylate was more modestly reduced (20% of the level seen in the wild-type). In contrast to the in vitro results, ime2-T242A mutant cells were still capable of forming spores (albeit with reduced efficiency and kinetics compared with wild-type cells) whereas the ime2-Y244F mutant failed to form spores. Thus, there was not a correlation between the autocatalytic readout and in vivo function in this previous study. Our demonstration that the major site of Ime2p autophosphorylation is in its activation loop provides an explanation for this apparent paradox. These data indicate that the T242A substitution dramatically reduced autophosphorylation not because it was catalytically inactive but because it lacked the major phosphoacceptor site. Our results suggest that even in the absence of Tyr244 phosphorylation that Thr242 can be phosphorylated via an autocatalytic mechanism. We infer that autophosphorylation of Thr242 promotes the Ime2p activity based on the phenotypes of the T242A mutant but suggest that this reaction is insufficient to efficiently promote sporulation in the absence of Tyr244 phosphorylation.

The in vitro reactions indicate that autophosphorylation of Thr242 is reduced by ~80% in the Y244F mutant (13).3 This mutant shows a similar decrease in phosphorylation of Ndt80p, a known Ime2p substrate, indicating that this substitution impairs autophosphorylation and phosphorylation of substrates to similar extents. These results suggest that Tyr244 phosphorylation promotes Thr242 autophosphorylation. Based on these data we propose that phosphorylation of Tyr244 by an upstream kinase is a key initiating step that must occur in order to activate Ime2p, and that Ime2p autophosphorylates its activation loop on Thr242 to further enhance its activity. The finding that the Ime2p activation loop is phosphorylated on Tyr244 alone, on both Tyr244 and Thr242, but not on Thr242 alone is consistent with a 2-step activation model (34). Interestingly, we find that a catalytically inactive form of Ime2p fails to be fully modified by phosphorylation in sporulation-competent cells that contain wild-type Ime2p even when Ime2p is overproduced (Fig. 4). This result suggests that Ime2p phosphorylates itself through an obligatory intramolecular mechanism and that autocatalysis is required for it to become fully hyperphosphorylated. These data do not necessarily indicate that the majority of the phosphorylated residues in Ime2p are the consequence of intramolecular autocatalysis. It is possible that an early autocatalytic event, or the acquisition of catalytic activity is required for Ime2p to become associated with additional proteins that are necessary for it to become further modified by other protein kinases. Additional studies will be necessary to elucidate the underlying mechanisms that couple catalytic activity of Ime2p to its hyperphosphorylation.

Which kinase phosphorylates Tyr244? Both genetic and biochemical studies indicate that Ime2p produced in mitotic cells can become activated suggesting that the activating kinase is not meiosis-specific (10, 35). RIM11 encodes a dual-specificity protein kinase found in both mitotic and meiotic cells that is required for meiosis (36). RIM11 genetically interacts with IME2 and is an attractive candidate for an activating kinase. However, Ime2p ectopically expressed in mitosis is equally active in rim11-{Delta} and wild-type cells as assayed using autocatalysis (see supplementary data). These data indicate that Rim11p is not required for Ime2p activity during sporulation. In addition, mutants lacking the Ste7p, Mkk1p, Mkk2p, or Pbs2p MAPKKs are able to sporulate indicating that they are not uniquely required for Ime2p activation.4 Whereas Cak1p has thus far been shown to activate protein kinases via threonine phosphorylation, it has also been shown to phosphorylate a synthetic substrate on tyrosine (37). One possibility is that Cak1p, which is present in mitotic cells but transcriptionally up-regulated in meiosis, directly phosphorylates Ime2p on Tyr244. Ime2p is most similar to a family of mammalian protein kinases that include male-germ cell associated kinase (MAK) and intestinal cell kinase (ICK), which show significant similarity to both CDKs and MAPKs throughout their catalytic cores (14). These enzymes also contain a TXY motif in their activation loops. Recent work by Fu et al. (14) demonstrates that ICK autophosphorylates on tyrosine in its TXY motif and that the threonine is phosphorylated by an upstream kinase. The yeast Cak1p enzyme is able to phosphorylate the ICK activating threonine residue. Thus, while Cak1p-mediated phosphorylation and autophosphorylation can activate both mammalian ICK and yeast Ime2p, the Cak1p target site and secondary autophosphorylated residue appear to be reversed in the 2 kinases. The phosphoamino acid analysis showed that Ime2p autophosphorylates on both threonine and serine (Fig. 3). Our results show that Ime2p does not phosphorylate itself at Ser246 in its activation loop or at Ser520 or Ser625, the residues in the C terminus of Ime2p identified as phosphorylated in our MS analysis. Truncation mutants lacking the first 18 or the last 190 amino acids are still able to autophosphorylate on serine in vitro (data not shown). This suggests that the autophosphorylated serine(s) is located within the catalytic core or a loop region in the kinase. These data also suggest that another kinase(s) functions in the Ime2p phosphomodification pathway that phosphorylates Ime2p at Ser520 and Ser625 (see below).

Phosphorylation of the Ime2p C terminus and Its Role in Regulating MI—We found that Ime2p mutants containing alanine substitutions for Ser520 and Ser625 genetically interact with slk19-{Delta} and cdc14-1 FEAR network mutants. Cells lacking either SLK19, CDC14, or SPO12 are defective in exiting MI (17, 19, 20). As such, they show characteristic kinetic defects in progression through the meiotic divisions (persistent MI peaks and delayed execution of MII) and they often form dyads. The ime2-S520A/S625A mutants show a kinetic distribution of MI and MII products that are qualitatively similar to those seen in FEAR network mutants and also form dyads at a modestly increased frequency. Strikingly, all single and double S520A, S625A alleles of IME2 substantially increase dyad formation in the slk19 and cdc14-1 backgrounds (Fig. 6B). These data indicate that phosphorylation of Ime2p at Ser520 and Ser625 can play a role in regulating the unique MI-MII transition. The MS data identified Ser625 as being exclusively phosphorylated and Ser520 as being partially phosphorylated in Ime2p purified from cells undergoing the meiotic divisions. Electrophoretic mobility differences between wild-type Ime2 and the mutants containing S520A and/or S625A substitutions was detected around the time when the nuclear divisions were occurring and not earlier in the program. This observation suggests that most of the phosphorylation to Ser520 and Ser625 occurs after prophase. We were unable to detect any differences in catalytic activity between wild-type Ime2p and the Ime2p-S520A/S625 isolated from sporulating cells at different times post-induction using Ndt80p as a substrate (data not shown). Phosphorylation at these sites may therefore alter the activity of Ime2p by influencing its subcellular localization and/or substrate specificity instead of controlling gross catalytic activity.

Because it appears that Ser520 and Ser625 are not autophosphorylated in vitro, we suggest that another kinase(s) phosphorylates the C terminus of Ime2p at these positions. Ser520 lies within a potential Polo kinase consensus sequence ((D/E)X(S/T){Phi}X(D/E)) (518DHSLSN523) where the acidic residue at position +2 and hydrophobic residue at –1 are the most critical for recognition (38). CDC5, the budding yeast Polo homolog, is transcriptionally induced as the nuclear divisions are occurring. Cdc5p has also been shown to positively regulate the FEAR network in mitosis (39, 40). Furthermore, defects in the accumulation of higher molecular weight forms of Ime2p in cdc5 mutants have been described (40). One of the many functions of Cdc5 may therefore be to phosphorylate Ime2p at Ser520. Ser625 is located within a highly basic region of the protein (623KKSREK628) and, to our knowledge, is not located within an obvious phosphorylation consensus motif.

Ime2p and Cdc28p are key interacting members of the protein kinase network that governs meiotic development (3). Cdc28p is controlled by activating and inactivating phosphorylation and by the binding of activator and inhibitor molecules. Ime2p is required for multiple meiotic events but little is known about its regulation. We propose that a phosphomodification pathway exists that is central to the activation and regulation of this enzyme. Ime2p activation is the first step in this pathway and requires Cak1p and a TXY motif in its activation loop. The phenotypes that we observed in our C-terminal phosphosite mutants show that specific regulatory modifications occur in this region of Ime2p. Because Ime2p is central to meiotic progression deciphering this pathway will be key to understanding how meiosis is controlled.


    FOOTNOTES
 
* This work was supported by National Institutes of Health Grant GM061817 (to E. W.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

Formula The on-line version of this article (available at http://www.jbc.org) contains supplementary materials. Back

1 To whom correspondence should be addressed: Dept. of Biochemistry and Molecular Biology, Thomas Jefferson University, 233 South 10th St., Philadelphia, PA, 19107. Tel.: 215-503-4139; Fax: 215-923-9162; E-mail: edward.winter{at}jefferson.edu.

2 The abbreviations used are: CDK, cyclin-dependent kinase; MAPK, mitogen-activated protein kinase; FEAR, CDC fourteen early anaphase release; DAPI, 4',6-diamidino-2-phenylindole; HA, hemagglutinin. Back

3 K. Schindler, unpublished observations. Back

4 E. Winter, unpublished data. Back


    ACKNOWLEDGMENTS
 
We thank Allison Martin, Dean Dawson, and Kirsten Benjamin for strains and plasmids, Jeffrey Benovic for advice on phosphoamino acid analysis, Jonathan Chernoff for advice and assistance with phosphopeptide mapping, and Alexander Shaw for helpful discussions. We thank Randy Strich, Brendan Maher, and Noreen Ahmed for comments on this manuscript. The mass spectrometry analysis was performed under the direction of Nicholas Sherman in the W. M. Keck Biomedical Mass Spectrometry Laboratory at the University of Virginia Biomedical Research Facility with funding from the University of Virginia Pratt Committee.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Mitchell, A. P., Driscoll, S. E., and Smith, H. E. (1990) Mol. Cell. Biol. 10, 2104–2110[Abstract/Free Full Text]
  2. Chu, S., DeRisi, J., Eisen, M., Mulholland, J., Botstein, D., Brown, P. O., and Herskowitz, I. (1998) Science 282, 699–705[Abstract/Free Full Text]
  3. Honigberg, S. M. (2004) J. Cell. Biochem. 92, 1025–1033[CrossRef][Medline] [Order article via Infotrieve]
  4. Benjamin, K. R., Zhang, C., Shokat, K. M., and Herskowitz, I. (2003) Genes Dev. 17, 1524–1539[Abstract/Free Full Text]
  5. Guttmann-Raviv, N., Boger-Nadjar, E., Edri, I., and Kassir, Y. (2001) Genetics 159, 1547–1558[Abstract/Free Full Text]
  6. Clifford, D. M., Stark, K. E., Gardner, K. E., Hoffmann-Benning, S., and Brush, G. S. (2005) Cell Cycle 4, 1826–1833[Medline] [Order article via Infotrieve]
  7. Sopko, R., Raithatha, S., and Stuart, D. (2002) Mol. Cell. Biol. 22, 7024–7040[Abstract/Free Full Text]
  8. Pak, J., and Segall, J. (2002) Mol. Cell. Biol. 22, 6417–6429[Abstract/Free Full Text]
  9. Guttmann-Raviv, N., Martin, S., and Kassir, Y. (2002) Mol. Cell. Biol. 22, 2047–2056[Abstract/Free Full Text]
  10. Bolte, M., Steigemann, P., Braus, G. H., and Irniger, S. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 4385–4390[Abstract/Free Full Text]
  11. Purnapatre, K., Gray, M., Piccirillo, S., and Honigberg, S. M. (2005) Mol. Cell. Biol. 25, 440–450[Abstract/Free Full Text]
  12. Donzeau, M., and Bandlow, W. (1999) Mol. Cell. Biol. 19, 6110–6119[Abstract/Free Full Text]
  13. Schindler, K., Benjamin, K. R., Martin, A., Boglioli, A., Herskowitz, I., and Winter, E. (2003) Mol. Cell. Biol. 23, 8718–8728[Abstract/Free Full Text]
  14. Fu, Z., Schroeder, M. J., Shabanowitz, J., Kaldis, P., Togawa, K., Rustgi, A. K., Hunt, D. F., and Sturgill, T. W. (2005) Mol. Cell. Biol. 25, 6047–6064[Abstract/Free Full Text]
  15. Jaspersen, S. L., Charles, J. F., Tinker-Kulberg, R. L., and Morgan, D. O. (1998) Mol. Biol. Cell 9, 2803–2817[Abstract/Free Full Text]
  16. Stegmeier, F., Visintin, R., and Amon, A. (2002) Cell 108, 207–220[CrossRef][Medline] [Order article via Infotrieve]
  17. Marston, A. L., Lee, B. H., and Amon, A. (2003) Dev Cell 4, 711–726[CrossRef][Medline] [Order article via Infotrieve]
  18. Marston, A. L., and Amon, A. (2004) Nat. Rev. Mol. Cell. Biol. 5, 983–997[CrossRef][Medline] [Order article via Infotrieve]
  19. Kamieniecki, R. J., Liu, L., and Dawson, D. S. (2005) Cell Cycle 4, 1093–1098[Medline] [Order article via Infotrieve]
  20. Buonomo, S. B., Rabitsch, K. P., Fuchs, J., Gruber, S., Sullivan, M., Uhlmann, F., Petronczki, M., Toth, A., and Nasmyth, K. (2003) Dev Cell 4, 727–739[CrossRef][Medline] [Order article via Infotrieve]
  21. Sia, R. A., and Mitchell, A. P. (1995) Mol. Cell. Biol. 15, 5279–5287[Abstract]
  22. Boyle, W. J., Van Der Geer, P., and Hunter, T. (1991) in Methods in Enzymology (Hunter, T., and Sefton, B. M., eds) Vol. 201, pp. 110–149, Harcourt Brace Jovanovich, Pasadena, CA[Medline] [Order article via Infotrieve]
  23. Kaldis, P., Sutton, A., and Solomon, M. J. (1996) Cell 86, 553–564[CrossRef][Medline] [Order article via Infotrieve]
  24. Espinoza, F. H., Farrell, A., Erdjument-Bromage, H., Tempst, P., and Morgan, D. O. (1996) Science 273, 1714–1717[Abstract/Free Full Text]
  25. Rice, L. M., Plakas, C., and Nickels, J. T., Jr. (2005) Eukaryot. Cell 4, 55–62[Abstract/Free Full Text]
  26. Strich, R., Mallory, M. J., Jarnik, M., and Cooper, K. F. (2004) Genetics 167, 1621–1628[Abstract/Free Full Text]
  27. Dirick, L., Goetsch, L., Ammerer, G., and Byers, B. (1998) Science 281, 1854–1857[Abstract/Free Full Text]
  28. Nolen, B., Taylor, S., and Ghosh, G. (2004) Mol. Cell 15, 661–675[CrossRef][Medline] [Order article via Infotrieve]
  29. Canagarajah, B. J., Khokhlatchev, A., Cobb, M. H., and Goldsmith, E. J. (1997) Cell 90, 859–869[CrossRef][Medline] [Order article via Infotrieve]
  30. Lochhead, P. A., Sibbet, G., Morrice, N., and Cleghon, V. (2005) Cell 121, 925–936[CrossRef][Medline] [Order article via Infotrieve]
  31. Ge, B., Gram, H., Di Padova, F., Huang, B., New, L., Ulevitch, R. J., Luo, Y., and Han, J. (2002) Science 295, 1291–1294[Abstract/Free Full Text]
  32. Eyers, P. A., Erikson, E., Chen, L. G., and Maller, J. L. (2003) Curr. Biol. 13, 691–697[CrossRef][Medline] [Order article via Infotrieve]
  33. Abe, M. K., Kahle, K. T., Saelzler, M. P., Orth, K., Dixon, J. E., and Rosner, M. R. (2001) J. Biol. Chem. 276, 21272–21279[Abstract/Free Full Text]
  34. Ferrell, J. E., Jr., and Bhatt, R. R. (1997) J. Biol. Chem. 272, 19008–19016[Abstract/Free Full Text]
  35. Clifford, D. M., Marinco, S. M., and Brush, G. S. (2004) J. Biol. Chem. 279, 6163–6170[Abstract/Free Full Text]
  36. Bowdish, K. S., Yuan, H. E., and Mitchell, A. P. (1994) Mol. Cell. Biol. 14, 7909–7919[Abstract/Free Full Text]
  37. Zhu, H., Bilgin, M., Bangham, R., Hall, D., Casamayor, A., Bertone, P., Lan, N., Jansen, R., Bidlingmaier, S., Houfek, T., Mitchell, T., Miller, P., Dean, R. A., Gerstein, M., and Snyder, M. (2001) Science 293, 2101–2105[Abstract/Free Full Text]
  38. Nakajima, H., Toyoshima-Morimoto, F., Taniguchi, E., and Nishida, E. (2003) J. Biol. Chem. 278, 25277–25280[Abstract/Free Full Text]
  39. Lee, B. H., and Amon, A. (2003) Science 300, 482–486